Abstract: Objective To detect the plasma plasminogen activator inhibitor-1(PAI-1) and urokinase-type plasminogen activator (uPA) levels in PCOS and control of different BMI. Methods This experiment is divided into PCOS group and control group,PCOS group also divided into obesity and without obesity.To assay plasma PAI-1 and serum uPA of PCOS with and without obesity with enzyme-linked immunosurbent assay(ELISA),and meassure body mass index(BMI), waist hip ratio(WHR), blood glucose,fasting insulin and IRT.To evaluate insulin resistance with Homa Model and measure insulin area under curve (AUC). Results LH/FSH , T, blood glucose, HOMA-IR, AUC and the plasma level of PAI-1 were significantly increased in PCOS compared with normal control,and HOMA-IR, AUC and the plasma level of PAI-1 were also increased in obesity compared with non-obesity of PCOS (P<0.05). In the Spearman bivariate correlation analysis,significant correlation were found between PAI-1 and HOMA-IR,PAI-1 and AUC,PAI-1 and BMI,HOMA-IR and BMI (P<0.0001). Conclusion The increasing of PAI-1 is the result of metabolism disorder with hyperinsulinism and obesity.PAI-1 is one of evalution marker of insulin resistance.Anti-PAI-1 study maybe a new way to prevent obesity and insulin resistance.

Key words: plasminogen activator inhibitor-1, urokinase-type plasminogen activator (uPA), insulin resistance, obesity